On June 22, 2026, telehealth company LifeMD (Nasdaq: LFMD) announced an exclusive co-marketing agreement with Halozyme Therapeutics' Antares Pharma to launch a direct-to-patient, self-pay program for XYOSTED (testosterone enanthate) injection, with the offering slated to go live in July 2026. XYOSTED is an FDA-approved, once-weekly subcutaneous testosterone auto-injector designed for at-home use — a needle-based alternative to the gels, pellets, and clinic visits that dominate testosterone replacement therapy (TRT). The deal makes LifeMD the exclusive telehealth channel pairing a branded, FDA-approved injectable with a cash-pay virtual care model.

Why It Matters

Male sexual health telehealth has been one of sex tech's reliable growth engines, but most of the money has flowed through compounded and generic products vulnerable to FDA enforcement. LifeMD's XYOSTED deal signals a maturation: branded pharma manufacturers are now actively courting telehealth platforms as a primary commercialization channel, and self-pay cash models let them sidestep payer friction entirely. For investors, it's a read on whether men's-health telehealth can build durable, exclusive product moats rather than racing to the bottom on commodity generics. For the broader TRT market — riding deregulation momentum and a potential libido indication — it's an early marker of how the post-Schedule III landscape will be sold.

The agreement positions LifeMD against the booming compounded-testosterone trade that platforms like Hims & Hers have ridden to soaring valuations. Where compounded TRT lives in a regulatory gray zone, XYOSTED is a fully approved branded product, and LifeMD is betting that men will pay out of pocket for a name-brand auto-injector delivered through a virtual clinic rather than navigating insurance prior-authorizations or in-office injections. The structure mirrors the wider telehealth playbook of bolting a recognizable branded drug onto a subscription-style care funnel — the same logic behind LifeMD's existing GLP-1 partnerships for Wegovy and Eli Lilly's orforglipron.

The timing tracks a regulatory tailwind. An FDA expert panel in December 2025 recommended removing testosterone from its Schedule III controlled-substance classification and expanding approved indications, and in April 2026 the FDA opened a pathway inviting TRT sponsors to seek a new "low libido" indication. Testosterone prescribing is surging — reporting out of Texas in June 2026 documented skyrocketing use — and a branded, self-pay injectable gives LifeMD a differentiated lane as the category professionalizes beyond compounded peptides and gray-market clinics.

Sources

Update — 2026-06-28

Initial entry — story first created.